Crizotinib reimbursement criteria

The original drug Crizotinib (Crizotinib) has been launched in China and is included in the scope of medical insurance, but it is only reimbursable by medical insurance for patients who meet the indications, including patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer or ROS1-positive advanced non-small cell lung cancer (NSCLC). Patients who do not meet the conditions can only purchase it at their own expense. The current price of imported drugs is still relatively high. ALK and ROS1 belong to a family of proteins called receptor tyrosine kinases (RTKs), which are involved in cell growth. Crizotinib works primarily by blocking the activity of ALK or ROS1 when genetic changes are present, thereby reducing the growth and spread of cancer in ALK-positive ALCL and IMT and ALK- and ROS1-positive non-small cell lung cancer.